Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067187 | 0.98 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL16660269 | 0.88 | CYP1A2 (0.33) | CYP1A2CYP2C9CYP2D6CYP2C19NPSR1 | |
| Trolamine SCHEMBL2489430 | 0.87 | ALDH1A1 (0.39) | CYP1A2CYP2C9CYP2D6CYP2C19NPSR1 | |
| Monoethanolamine SCHEMBL7890670 | 0.87 | ALDH1A1 (0.47) | CYP1A2CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL1273910 | 0.87 | LCK (0.44) | CYP2D6LCKHSD17B10HIF1ATSHR | |
| SCHEMBL62953 | 0.87 | ALDH1A1 (0.44) | CYP1A2CYP2C9LCKHSD17B10HIF1A | |
| SCHEMBL62067 | 0.87 | ALDH1A1 (0.44) | CYP1A2CYP2C9LCKHSD17B10HIF1A | |
| SCHEMBL578516 | 0.87 | LCK (0.44) | CYP2D6LCKHSD17B10HIF1ATSHR | |
| SCHEMBL97470 | 0.87 | MAPT (0.42) | CYP1A2CYP2C9CYP2D6CYP2C19NPSR1 | |
| SCHEMBL8990 | 0.87 | MAPT (0.42) | CYP1A2CYP2C9CYP2D6CYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016922-B2 | Stabilized aqueous antibody compositions | ARECOR LIMITED (GB) | 2024-06-25 | — | — | US | disclosed |
| WO-2024110381-A1 | IONIZABLE LIPIDS AND LIPID NANOPARTICLES CONTAINING THEREOF | CERTEST BIOTEC, S.L. (ES) | 2024-05-30 | — | — | WO | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-11524937-B2 | Indirubin derivatives, and uses thereof | CITY OF HOPE (US) | 2022-12-13 | — | — | US | disclosed |
| EP-3412694-B1 | AQUEOUS DISPERSION, METHOD FOR MANUFACTURING THE SAME, AND IMAGE FORMING METHOD | FUJIFILM CORP (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20200138946-A1 | STABILIZED AQUEOUS ANTIBODY COMPOSITIONS | ARECOR LIMITED (GB) | 2020-05-07 | — | — | US | disclosed |
| WO-2019101853-A1 | TREATMENT OF SKIN DISORDERS | PIQUR THERAPEUTICS AG (CH) | 2019-05-31 | — | — | WO | disclosed |
| US-20180134753-A1 | BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES | THE JOHNS HOPKINS UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-20180028455-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-01 | — | — | US | disclosed |
| US-9802984-B2 | Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20120065114-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | THE PROCTER & GAMBLE COMPANY (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110207643-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | THE PROCTER & GAMBLE COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110082064-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | THE PROCTER & GAMBLE COMPANY (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100234258-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | THE PROCTER & GAMBLE COMPANY (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100041573-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | THE PROCTER & GAMBLE COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090131294-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | BETTIOL JEAN-LUC PHILIPPE | 2009-05-21 | — | — | US | disclosed |
| US-20080227676-A1 | Amine reaction compounds comprising one or more active ingredient | PROCTER & GAMBLE COMPANY, THE | 2008-09-18 | — | — | US | disclosed |
| CN-101175558-A | Dispersing agent | NOVEON INC (US) | 2008-05-07 | — | — | CN | disclosed |
| US-20070232507-A1 | Amine reaction compounds comprising one or more active ingredient | THE PROCTER & GAMBLE COMPANY ATTENTION: CHIEF PATENT COUNSEL (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070099818-A1 | Amine reaction compounds comprising one or more active ingredient | THE PROCTER & GAMBLE COMPANY (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524937-B2 | Indirubin derivatives, and uses thereof | HCCS, ABL1, MAP3K7 | CYP1A2 763/4885CYP2C9 1652/4885CYP2D6 1695/4885 |
| US-20100041573-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | MAOA, MAOB, CMA1 | CYP1A2 108/4885CYP2C9 140/4885CYP2D6 268/4885 |
| US-20110082064-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | MAOA, MAOB, CMA1 | CYP1A2 108/4885CYP2C9 140/4885CYP2D6 268/4885 |
| US-20110207643-A1 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT | MAOA, MAOB, CMA1 | CYP1A2 108/4885CYP2C9 140/4885CYP2D6 268/4885 |
| US-20200138946-A1 | STABILIZED AQUEOUS ANTIBODY COMPOSITIONS | IGLV6-57, FCGRT, PA2G4 | CYP1A2 4874/4885CYP2C9 4868/4885CYP2D6 4872/4885 |
| US-20180134753-A1 | BIOMIMETIC PEPTIDE AND BIODEGRADABLE DELIVERY PLATFORM FOR THE TREATMENT OF ANGIOGENESIS- AND LYMPHANGIOGENESIS-DEPENDENT DISEASES | VEGFA, LRRFIP1, FLT1 | CYP1A2 4874/4885CYP2C9 4814/4885CYP2D6 4719/4885 |
| US-12016922-B2 | Stabilized aqueous antibody compositions | IGLV6-57, FCGRT, PA2G4 | CYP1A2 4874/4885CYP2C9 4868/4885CYP2D6 4872/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | CYP1A2 4505/4885CYP2C9 4548/4885CYP2D6 3886/4885 |
| US-20180028455-A1 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | VEGFA, IAPP, FLT1 | CYP1A2 4850/4885CYP2C9 4719/4885CYP2D6 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.